CN106723084A - 大豆低聚肽饮品及制备方法和在特医配方食品中的应用 - Google Patents
大豆低聚肽饮品及制备方法和在特医配方食品中的应用 Download PDFInfo
- Publication number
- CN106723084A CN106723084A CN201710053231.2A CN201710053231A CN106723084A CN 106723084 A CN106723084 A CN 106723084A CN 201710053231 A CN201710053231 A CN 201710053231A CN 106723084 A CN106723084 A CN 106723084A
- Authority
- CN
- China
- Prior art keywords
- parts
- soybean oligopeptide
- drink
- acid
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 119
- 244000068988 Glycine max Species 0.000 title claims abstract description 117
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 114
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 114
- 235000013305 food Nutrition 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000001509 sodium citrate Substances 0.000 claims abstract description 34
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 239000002253 acid Substances 0.000 claims abstract description 24
- 235000001014 amino acid Nutrition 0.000 claims abstract description 24
- 150000001413 amino acids Chemical class 0.000 claims abstract description 24
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 24
- 239000003765 sweetening agent Substances 0.000 claims abstract description 24
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 23
- 239000011707 mineral Substances 0.000 claims abstract description 23
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 22
- 239000011720 vitamin B Substances 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 21
- 239000002131 composite material Substances 0.000 claims abstract description 20
- 229940046001 vitamin b complex Drugs 0.000 claims abstract description 19
- 235000011083 sodium citrates Nutrition 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 238000002156 mixing Methods 0.000 claims description 28
- 238000011049 filling Methods 0.000 claims description 21
- 239000000706 filtrate Substances 0.000 claims description 20
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 19
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical group OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 18
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 18
- 235000015165 citric acid Nutrition 0.000 claims description 18
- 235000011090 malic acid Nutrition 0.000 claims description 18
- 239000001630 malic acid Substances 0.000 claims description 18
- 239000012669 liquid formulation Substances 0.000 claims description 14
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 13
- 239000012467 final product Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 238000011017 operating method Methods 0.000 claims description 13
- 229940013618 stevioside Drugs 0.000 claims description 13
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 13
- 235000019202 steviosides Nutrition 0.000 claims description 13
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 12
- 229910052749 magnesium Inorganic materials 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 10
- 239000004384 Neotame Substances 0.000 claims description 10
- 229910052804 chromium Inorganic materials 0.000 claims description 10
- 239000011651 chromium Substances 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 10
- 235000019412 neotame Nutrition 0.000 claims description 10
- 108010070257 neotame Proteins 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 239000004376 Sucralose Substances 0.000 claims description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- 235000019408 sucralose Nutrition 0.000 claims description 8
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 8
- 239000011726 vitamin B6 Substances 0.000 claims description 8
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 239000011715 vitamin B12 Substances 0.000 claims description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 5
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229960003067 cystine Drugs 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 229940055726 pantothenic acid Drugs 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 abstract description 15
- 208000034767 Hypoproteinaemia Diseases 0.000 abstract description 8
- 230000002980 postoperative effect Effects 0.000 abstract description 8
- 206010052428 Wound Diseases 0.000 abstract description 6
- 208000027418 Wounds and injury Diseases 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 230000007661 gastrointestinal function Effects 0.000 abstract description 2
- 230000035876 healing Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 24
- 235000016709 nutrition Nutrition 0.000 description 21
- 235000013350 formula milk Nutrition 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 235000013361 beverage Nutrition 0.000 description 12
- 241000371652 Curvularia clavata Species 0.000 description 11
- 108010064851 Plant Proteins Proteins 0.000 description 11
- 235000021118 plant-derived protein Nutrition 0.000 description 11
- 235000020195 rice milk Nutrition 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 239000000835 fiber Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000035764 nutrition Effects 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000011716 vitamin B2 Substances 0.000 description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 229930189775 mogroside Natural products 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 6
- 229930064664 L-arginine Natural products 0.000 description 6
- 235000014852 L-arginine Nutrition 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- 102000004506 Blood Proteins Human genes 0.000 description 5
- 108010017384 Blood Proteins Proteins 0.000 description 5
- 229960005069 calcium Drugs 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 235000008935 nutritious Nutrition 0.000 description 4
- 229940091258 selenium supplement Drugs 0.000 description 4
- 229930003270 Vitamin B Natural products 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000241257 Cucumis melo Species 0.000 description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 1
- 206010066963 Procedural vomiting Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015015 brainstem development Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940107218 chromium Drugs 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/56—Flavouring or bittering agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
本发明属于特殊医学用途配方食品技术领域,特别涉及大豆低聚肽饮品及制备方法和在特医配方食品中的应用。该大豆低聚肽饮品包括以下原料:大豆低聚肽、复合酸味剂、复合甜味剂、柠檬酸钠、氨基酸、维生素B族,矿物质。本发明大豆低聚肽饮品组方科学、合理,对胃肠道功能不全、肠内营养管饲、低蛋白血症及术后伤口愈合不良等具有显著治疗效果,针对性强,可作为特殊医学用途配方食品。
Description
(一)技术领域
本发明属于特殊医学用途配方食品技术领域,特别涉及大豆低聚肽饮品及制备方法和在特医配方食品中的应用。
(二)背景技术
特殊医学用途配方食品主要是为了满足由于进食限制、消化吸收障碍或代谢紊乱人群的每日营养需要。在全球范围内,特殊医学用途配方食品的市场规模为北美300亿元左右,欧洲140亿元左右,日本100亿元左右,而中国市场仅有6亿元左右,占全球市场规模的1%。特殊医学用途配方食品在中国有近30多年的使用历史,以往都是按照药品进行管理,2010-2013年间《特殊医学用途配方食品通则》、《特殊医学用途配方食品良好生产规范》、《特殊医学用途婴儿配方食品通则》标准相继出台以及2015年特殊医学用途配方食品被列入《食品安全法》等一系列举措,足见国家逐步对这一领域开始重视并发展。
大豆低聚肽在食品中的应用主要集中在普通食品和保健品中,能在一定程度上起到增强免疫力、解除疲劳、提高运动能力的功效,侧重于良好口感与运动中补充身体机能的效果;加入大豆低聚肽的产品在一定程度上具有降血压、促进睡眠、减肥、美容等生理功能。然而,现有产品一般只是通过添加单一的大豆低聚肽成分,或者,添加和大豆低聚肽功效相似的辅助制剂,导致这类产品在普通产品和保健品中所能发挥的功效并不理想。而特殊医学用途配方食品所需满足的人群具有一定的特殊性,其不仅对服用的产品提出了医学治疗要求,更重要的,其是区别于现有单纯治疗效用的药物,达到药食同源,须以食品代替药物并给人体以治疗和保健呵护,这就对能应用于该领域的配方食品提出了较高的要求。
目前的保健饮料及保健饮品通常只能起到一定的调节机体和营养保健的效用,对于可应用于特殊医学用途配方食品并满足重症患者,进食限制、消化吸收障碍或代谢紊乱人群的每日营养需要的功效饮品并未见报道。
(三)发明内容
本发明为了弥补现有技术的不足,提供了一种组方科学、合理,对胃肠道功能不全、肠内营养管饲、低蛋白血症及术后伤口愈合不良等患者具有显著营养补充及治疗功效,针对性强,可作为特殊医学用途配方食品的大豆低聚肽饮品及制备方法和在特医配方食品中的应用,解决了现有技术中存在的问题。
本发明是通过如下技术方案实现的:
一种大豆低聚肽饮品,其活性成分包括以下重量份数的原料:大豆低聚肽8-20份、复合甜味剂0.13-2.2份、复合酸味剂0.3-0.6份、柠檬酸钠0.02-0.1份、维生素B族0.0001-0.05份、矿物质0.001-0.2份。
其活性成分还包括氨基酸0.3-10份。
所述大豆低聚肽饮品的剂型为液态制剂;所述液态制剂的原料组成为:大豆低聚肽8-20份、复合甜味剂0.13-2.2份、复合酸味剂0.3-0.6份、柠檬酸钠0.02-0.1份、维生素B族0.0001-0.05份、矿物质0.001-0.2份、纯净水64-94份。
所述大豆低聚肽饮品的剂型为液态制剂或固态制剂;所述液态制剂的原料组成为:大豆低聚肽8-20份、复合甜味剂0.13-2.2份、复合酸味剂0.3-0.6份、柠檬酸钠0.02-0.1份、氨基酸0.3-10份、维生素B族0.0001-0.05份、矿物质0.001-0.2份、纯净水64-94份;所述固态制剂的原料组成为大豆低聚肽8-20份、复合甜味剂0.13-2.2份、复合酸味剂0.3-0.6份、柠檬酸钠0.02-0.1份、氨基酸0.3-10份、维生素B族0.0001-0.05份、矿物质0.001-0.2份。
所述大豆低聚肽液体渗透压为280-320mOsm/L;所述氨基酸为L-谷氨酰胺、L-瓜氨酸、L-半胱氨酸、L-胱氨酸、L-精氨酸、丙氨酸的一种或多种;所述复合甜味剂为赤藓糖醇、三氯蔗糖、纽甜、甜菊糖、罗汉果甜苷中的两种或多种;所述复合酸味剂为柠檬酸和苹果酸的组合;所述维生素B族为维生素B2、维生素B6、维生素B12、烟酸(B3)、泛酸(B5)、生物素酸(B7)、叶酸(B9)的一种或多种;所述矿物质为钙、镁、铬、硒、铁、锌元素的一种或多种。
一种制备大豆低聚肽饮品的液态制剂的方法,包括如下操作步骤:
(1)混料:按上述重量份数,将复合甜味剂、复合酸味剂、柠檬酸钠、维生素B族及矿物质按照等量递增的方式进行预混,得预混料,备用;
(2)向步骤(1)的预混料中加入上述重量份数的大豆低聚肽,混和均匀,得混料A,备用;
(3)溶解:取上述重量份数的纯净水,加热至20-50℃,然后将混料A缓慢倒入纯净水中,搅拌至充分溶解,得混合液,备用;
(4)过滤:将步骤(3)的混合液采用孔径0.30-1.0μm的滤膜,在<1.0MPa压力条件下进行纸板过滤,得滤液,备用;
(5)灌装、灭菌:将步骤(4)的滤液灌装,于100-121℃灭菌1-30min,即得。
一种制备大豆低聚肽饮品的液态制剂的方法,包括如下操作步骤:
(1)混料:按上述重量份数,将复合甜味剂、复合酸味剂、柠檬酸钠、氨基酸、维生素B族及矿物质按照等量递增的方式进行预混,得预混料,备用;
(2)向步骤(1)的预混料中加入上述重量份数的大豆低聚肽,混和均匀,得混料B,备用;
(3)溶解:取上述重量份数的纯净水,加热至20-50℃,然后将混料B缓慢倒入纯净水中,搅拌至充分溶解,得混合液,备用;
(4)过滤:将步骤(3)的混合液采用孔径0.30-1.0μm的滤膜,在<1.0MPa压力条件下进行纸板过滤,得滤液,备用;
(5)灌装、灭菌:将步骤(4)的滤液灌装,于100-121℃灭菌1-30min,即得;
一种制备大豆低聚肽饮品的固态制剂的方法,包括如下操作步骤:
(1)混料:按上述重量份数,将复合甜味剂、复合酸味剂、柠檬酸钠、氨基酸、维生素B族及矿物质按照等量递增的方式进行预混,得预混料,备用;
(2)向步骤(1)的预混料中加入上述重量份数的大豆低聚肽,混和均匀,得混料C,备用;
(3)包装:将混料A紫外杀菌后,送入洁净包装间内包装,即得。
本发明大豆低聚肽饮品在特殊医学用途配方食品中的应用,可作为全面的营养补充剂,适用于胃肠功能不全患者、低蛋白血症患者、肠内营养管饲患者、高代谢疾病患者、术后切口愈合不良患者使用,无需按照医生推荐的各营养补充剂单独服用,且实际治疗中相比于单独服用单剂的营养补充剂,治疗周期短,疗效显著,针对性强;而且,该大豆低聚肽饮品可与现有特殊医学配方食品配合、作为伴侣共同食用,疗效更显著、更好。
用法用量:需在医生或营养师指导下使用。本发明大豆低聚肽饮品的液态制剂瓶装,100-300mL/瓶,直接服用或管饲,每日1-3次,每次1-2瓶。本发明大豆低聚肽饮品的固态制剂,10-30g/袋,溶解于10倍水中服用或管饲,每日1-3次,每次1-2袋。
本发明的各活性成分的作用如下:
大豆低聚肽采用多级定向酶解技术制备而成,由2-10个氨基酸残基分子组成,分子量分布均匀(150-1500Da),低聚肽含量约98%,游离氨基酸含量1-2%,无需消化可直接吸收,迅速提供氮源,纠正负氮平衡,促进伤口愈合且大豆肽的风味、口感、营养价值高,短肽成分与人体氨基酸谱最接近,并且无抗原性,低致敏性;用于术后病人补充蛋白质使用,可达到促进伤口愈合,更快的改善机体的营养状况,提高免疫力的功效;还具有吸收速度快、高效纠正负氮平衡、提高血浆蛋白水平、促进伤口愈合的优势。
L-谷氨酰胺能有效提高氮源利用率,提高免疫力,保护肠功能,减少感染;L-瓜氨酸可提高身体免疫力,维持正常的血糖平衡,保护器官机能。L-半胱氨酸具有解毒效果,可改善炎症和过敏反应,并能有效的预防和治疗放射性伤害;L-胱氨酸可以促进伤口愈合,用于肝炎、放射性损伤的防治。L-精氨酸可促进伤口愈合、增进细胞***能力、提高机体免疫力。丙氨酸为组成人体蛋白质的20种氨基酸之一,可预防肾结石、协助葡萄糖代谢、改善身体能量。
赤藓糖醇作为天然、健康甜味剂,甜感清凉、爽口,降低不良风味,热值为零,可以降低液体制剂热量、同时不致血糖升高。罗汉果甜苷的甜度为蔗糖250-300倍,热量为零,可清热润肺镇咳、润肠通便,对糖尿病、便秘等有防治作用。本发明的任一两种甜味剂复合使用,相对于单纯使用单一甜味剂成本、用量大大减少,甜度更相比于单纯使用单一甜味剂增加。
维生素B2为体内黄酶类辅基的组分,对机体代谢障碍的预防有非常好的效果,能参与体内生物氧化与能量代谢;它与碳水化合物、蛋白质、核酸和脂肪的代谢有关,可提高机体对蛋白质的利用率,促进生长发育,维护皮肤和细胞膜的完整性。维生素B6与氨基酸代谢有关,是代谢中多种酶的辅酶组分。在预防术后呕吐、增强免疫力、抗癌等许多方面具有临床应用效果。维生素B12作为一种辅酶,能参与蛋白质的生物合成,具有促进神经***的健康功能,当缺乏时会影响人体正常生长发育。烟酸(VB3):人体必需的13种维生素之一,在人体内转化为烟酰胺,参与体内脂质代谢,预防赖皮病。泛酸(VB5):参与体内能量制造,是大脑和神经必需的营养物质,可加强皮肤水合功能,改善干燥、粗糙、脱屑、等皮肤病。生物素酸(VB7):有助于维生素B群利用,维护皮肤及毛发的正常运作和生长,减轻皮炎、预防白发和脱发、提高人体免疫力。叶酸(VB9):对细胞***生长及核酸、蛋白质合成有重要作用,促进红细胞成熟,促进胎儿大脑和神经***发育。
矿物质钙是骨骼发育的基本原料,还能调节体内某些酶的活性,参与神经、肌肉的活动和神经递质的释放,调节激素的分泌,促进伤口血液凝固、调节心律、降低心血管的通透性控制、维持酸碱平衡等多项生理功能。镁能参与能量、蛋白质及核酸代谢,可催化酶的活性,调控细胞增殖、分化。铬可促进蛋白质、脂质代谢,改善胰岛素水平,对促进生长发育具有疗效。硒抗氧化和抗癌作用,可抵抗衰老,预防克山病、心血管病、糖尿病、肝病、***病、心脏病、癌症等,运用于癌症、手术、放化疗期间。铁是人体必需微量元素,血红蛋白的重要部分,参与氧气运输和储存,预防和治疗因缺铁而引起的贫血,增加皮肤光泽。锌在人体生长发育、生殖遗传、免疫、内分泌等生理过程中起重要的作用,改善食欲,促进生长发育。不同种类维生素和矿物质联用,相互协同,共同促进机体恢复正常机能并维持健康状态。
本发明的大豆低聚肽饮品由大豆低聚肽、氨基酸、维生素B族及矿物质等活性成分制成,尤其适用于重创、术后虚弱及进食限制、消化吸收障碍、代谢紊乱人群服用。其中,大豆低聚肽所含氨基酸成分及含量评价值与人体更接近,营养价值高,易吸收,且具有高效纠正负氮平衡、提高血浆蛋白水平、促进伤口愈合的作用,这与重创后人体蛋白质代谢减慢、分解加快,氨基酸合成蛋白质减少等一系列机体状态形成互补;氨基酸尤其谷氨酰胺,作为营养补充剂,与大豆低聚肽混合可有效提高人体对氮源的利用率,提高免疫力,保护肠功能,减少感染,适于创伤、术后人群及肠胃功能较弱人群的营养补充;维生素B族尤其维生素B6、B12,与大豆低聚肽及氨基酸搭配,可在机体氮源获得充分而快速补充的同时,修复机体创伤;矿物质的添加,则增强维生素作为机体代谢辅酶的活性,上述各活性成分搭配,能对特殊代谢障碍及需进行营养补充的术后人群起到方便、充分而快速的调节机体、吸收营养、修复创伤的功效。病人无需繁琐的进行各种不同营养的选择及补充,而现有营养补充剂要么单一,要么难以获得充分的营养吸收,延缓术后病人的康复,无法真正起到及时、有效调节该类人群机体的免疫作用。
本发明大豆低聚肽饮品中的复合甜味剂和复合酸味剂的添加,不但能起到调节口感、增强适口性的作用,还能通过相互间特定种类及各种类特定量的搭配,与柠檬酸钠协同增强酸甜味口感,更能遮盖、消除大豆低聚肽的苦味,提升产品的品质。
本发明大豆低聚肽饮品通过预混、溶解、均质、过滤、包装制成固态或液态制剂,整体工艺简单、无副作用,可作为特殊医学用途配方食品的营养支持,在特殊医学用途配方食品中具有广阔的市场前景。
(四)具体实施方式
下面结合实施例对本发明作进一步说明,但本发明并不局限于此。
实施例1:
该大豆低聚肽饮品的制备方法,采用如下操作步骤:
(1)混料:按上述重量,将赤藓糖醇、罗汉果甜苷、柠檬酸、苹果酸、柠檬酸钠、维生素B6及钙元素按照等量递增的方式进行预混,得预混料,备用;
(2)向步骤(1)的预混料中加入上述重量的大豆低聚肽,混和均匀,得混料A,备用;
(3)溶解:取上述重量的纯净水,加热至20-50℃,放入搅拌罐内,然后将混料B缓慢倒入纯净水中,搅拌至充分溶解,得混合液,备用;
(4)过滤:将步骤(3)的混合液采用孔径0.30-1.0μm的滤膜,在<1.0MPa压力条件下进行纸板过滤,得滤液,备用;
(5)灌装、灭菌:将步骤(4)的滤液灌装,于100-121℃灭菌1-30min,即得。
实施例2
该大豆低聚肽饮品的制备方法,采用如下操作步骤:
(1)混料:按上述重量,将赤藓糖醇、三氯蔗糖、柠檬酸、苹果酸、柠檬酸钠、维生素B6及镁元素按照等量递增的方式进行预混,得预混料,备用;
(2)向步骤(1)的预混料中加入上述重量的大豆低聚肽,混和均匀,得混料A,备用;
(3)溶解:取上述重量的纯净水,加热至20-50℃,放入搅拌罐内,然后将混料B缓慢倒入纯净水中,搅拌至充分溶解,得混合液,备用;
(4)过滤:将步骤(3)的混合液采用孔径0.30-1.0μm的滤膜,在<1.0MPa压力条件下进行纸板过滤,得滤液,备用;
(5)灌装、灭菌:将步骤(4)的滤液灌装,于100-121℃灭菌1-30min,即得。
实施例3
大豆低聚肽饮品成分 | 含量(Kg) |
大豆低聚肽 | 20 |
赤藓糖醇 | 2 |
甜菊糖 | 0.1 |
柠檬酸 | 0.3 |
苹果酸 | 0.3 |
柠檬酸钠 | 0.1 |
维生素B12 | 0.0005 |
铬元素 | 0.03 |
纯净水 | 94 |
该大豆低聚肽饮品的制备方法,采用如下操作步骤:
(1)混料:按上述重量,将赤藓糖醇、甜菊糖、柠檬酸、苹果酸、柠檬酸钠、维生素B12及铬元素按照等量递增的方式进行预混,得预混料,备用;
(2)向步骤(1)的预混料中加入上述重量的大豆低聚肽,混和均匀,得混料A,备用;
(3)溶解:取上述重量的纯净水,加热至20-50℃,放入搅拌罐内,然后将混料B缓慢倒入纯净水中,搅拌至充分溶解,得混合液,备用;
(4)过滤:将步骤(3)的混合液采用孔径0.30-1.0μm的滤膜,在<1.0MPa压力条件下进行纸板过滤,得滤液,备用;
(5)灌装、灭菌:将步骤(4)的滤液灌装,于100-121℃灭菌1-30min,即得。
实施例4
大豆低聚肽饮品成分 | 含量(Kg) |
大豆低聚肽 | 9 |
赤藓糖醇 | 0.4 |
甜菊糖 | 0.03 |
纽甜 | 0.002 |
柠檬酸 | 0.25 |
苹果酸 | 0.15 |
柠檬酸钠 | 0.06 |
维生素B2 | 0.002 |
硒元素 | 0.01 |
纯净水 | 85 |
该大豆低聚肽饮品的制备方法,采用如下操作步骤:
(1)混料:按上述重量,将赤藓糖醇、甜菊糖、纽甜、柠檬酸、苹果酸、柠檬酸钠、维生素B2及铁元素按照等量递增的方式进行预混,得预混料,备用;
(2)向步骤(1)的预混料中加入上述重量的大豆低聚肽,混和均匀,得混料A,备用;
(3)溶解:取上述重量的纯净水,加热至20-50℃,放入搅拌罐内,然后将混料B缓慢倒入纯净水中,搅拌至充分溶解,得混合液,备用;
(4)过滤:将步骤(3)的混合液采用孔径0.30-1.0μm的滤膜,在<1.0MPa压力条件下进行纸板过滤,得滤液,备用;
(5)灌装、灭菌:将步骤(4)的滤液灌装,于100-121℃灭菌1-30min,即得。
实施例5
大豆低聚肽饮品成分 | 含量(Kg) |
大豆低聚肽 | 16 |
赤藓糖醇 | 1 |
甜菊糖 | 0.06 |
纽甜 | 0.001 |
柠檬酸 | 0.3 |
苹果酸 | 0.2 |
柠檬酸钠 | 0.08 |
维生素B2 | 0.004 |
铬元素 | 0.025 |
纯净水 | 90 |
该大豆低聚肽饮品的制备方法,采用如下操作步骤:
(1)混料:按上述重量,将赤藓糖醇、甜菊糖、纽甜、柠檬酸、苹果酸、柠檬酸钠、维生素B2及锌元素按照等量递增的方式进行预混,得预混料,备用;
(2)向步骤(1)的预混料中加入上述重量的大豆低聚肽,混和均匀,得混料A,备用;
(3)溶解:取上述重量的纯净水,加热至20-50℃,放入搅拌罐内,然后将混料B缓慢倒入纯净水中,搅拌至充分溶解,得混合液,备用;
(4)过滤:将步骤(3)的混合液采用孔径0.30-1.0μm的滤膜,在<1.0MPa压力条件下进行纸板过滤,得滤液,备用;
(5)灌装、灭菌:将步骤(4)的滤液灌装,于100-121℃灭菌1-30min,即得。
实施例6
大豆低聚肽饮品成分 | 含量(Kg) |
大豆低聚肽 | 8 |
赤藓糖醇 | 1 |
三氯蔗糖 | 0.03 |
柠檬酸 | 0.2 |
苹果酸 | 0.1 |
柠檬酸钠 | 0.02 |
维生素B6 | 0.0001 |
镁元素 | 0.001 |
纯净水 | 64 |
该大豆低聚肽饮品的制备方法同实施例2,此处不再详述。
实施例7
大豆低聚肽饮品成分 | 含量(Kg) |
大豆低聚肽 | 20 |
赤藓糖醇 | 2 |
甜菊糖 | 0.02 |
纽甜 | 0.002 |
柠檬酸 | 0.1 |
苹果酸 | 0.5 |
柠檬酸钠 | 0.1 |
维生素B2 | 0.05 |
铬元素 | 0.2 |
纯净水 | 94 |
该大豆低聚肽饮品的制备方法同实施例5,此处不再详述。
实施例8
大豆低聚肽饮品成分 | 含量(Kg) |
大豆低聚肽 | 13 |
赤藓糖醇 | 0.5 |
甜菊糖 | 0.06 |
罗汉果甜苷 | 0.02 |
柠檬酸 | 0.2 |
苹果酸 | 0.2 |
柠檬酸钠 | 0.08 |
L-精氨酸 | 2.5 |
L-谷氨酰胺 | 3.5 |
维生素B2 | 0.004 |
镁元素 | 0.02 |
纯净水 | 80 |
该大豆低聚肽饮品的制备方法,包括如下操作步骤:
(1)混料:按上述重量,将复合甜味剂、复合酸味剂、柠檬酸钠、氨基酸、维生素B族及矿物质按照等量递增的方式进行预混,得预混料,备用;
(2)向步骤(1)的预混料中加入上述重量的大豆低聚肽,混和均匀,得混料B,备用;
(3)溶解:取上述重量的纯净水,加热至20-50℃,放入搅拌罐内,然后将混料B缓慢倒入纯净水中,搅拌至充分溶解,得混合液,备用;
(4)过滤:将步骤(3)的混合液采用孔径0.30-1.0μm的滤膜,在<1.0MPa压力条件下进行纸板过滤,得滤液,备用;
(5)灌装、灭菌:将步骤(4)的滤液灌装,于100-121℃灭菌1-30min,即得。
实施例9
大豆低聚肽饮品成分 | 含量(Kg) |
大豆低聚肽 | 9 |
赤藓糖醇 | 0.4 |
甜菊糖 | 0.01 |
纽甜 | 0.001 |
罗汉果甜苷 | 0.01 |
三氯蔗糖 | 0.01 |
柠檬酸 | 0.1 |
苹果酸 | 0.3 |
柠檬酸钠 | 0.03 |
L-半胱氨酸 | 2.5 |
L-谷氨酰胺 | 2 |
L-精氨酸 | 3 |
维生素B2 | 0.003 |
铬元素 | 0.015 |
镁元素 | 0.018 |
纯净水 | 88 |
该大豆低聚肽饮品的制备方法同实施例8,此处不再详述。
实施例10
该大豆低聚肽饮品的制备方法同实施例8,此处不再详述。
实施例11
大豆低聚肽饮品成分 | 含量(Kg) |
大豆低聚肽 | 8 |
赤藓糖醇 | 1 |
三氯蔗糖 | 0.03 |
柠檬酸 | 0.2 |
苹果酸 | 0.1 |
L-谷氨酰胺 | 0.3 |
柠檬酸钠 | 0.05 |
维生素B6 | 0.0001 |
镁元素 | 0.001 |
纯净水 | 64 |
该大豆低聚肽饮品的制备方法同实施例8,此处不再详述。
实施例12
该大豆低聚肽饮品的制备方法同实施例8,此处不再详述。
实施例13
大豆低聚肽饮品成分 | 含量(Kg) |
大豆低聚肽 | 17 |
赤藓糖醇 | 0.5 |
甜菊糖 | 0.01 |
罗汉果甜苷 | 0.01 |
纽甜 | 0.002 |
柠檬酸 | 0.4 |
苹果酸 | 0.1 |
柠檬酸钠 | 0.09 |
L-精氨酸 | 2.5 |
L-谷氨酰胺 | 3.5 |
丙氨酸 | 1 |
维生素B2 | 0.004 |
维生素B12 | 0.01 |
镁元素 | 0.02 |
该大豆低聚肽饮品的制备方法,包括如下操作步骤:
(1)混料:按上述重量,将复合甜味剂、复合酸味剂、柠檬酸钠、氨基酸、维生素B族及矿物质按照等量递增的方式进行预混,得预混料,备用;
(2)向步骤(1)的预混料中加入上述重量的大豆低聚肽,混和均匀,得混料C,备用;
(3)包装:将混料A紫外杀菌后,送入洁净包装间内包装,即得。
实施例14
大豆低聚肽饮品成分 | 含量(Kg) |
大豆低聚肽 | 9 |
赤藓糖醇 | 0.4 |
甜菊糖 | 0.01 |
纽甜 | 0.001 |
罗汉果甜苷 | 0.01 |
三氯蔗糖 | 0.01 |
柠檬酸 | 0.1 |
苹果酸 | 0.3 |
柠檬酸钠 | 0.05 |
L-半胱氨酸 | 2.5 |
L-谷氨酰胺 | 2 |
L-精氨酸 | 3 |
维生素B2 | 0.003 |
铬元素 | 0.015 |
镁元素 | 0.018 |
该大豆低聚肽饮品的制备方法同实施例13,此处不再详述。
实施例15
该大豆低聚肽饮品的制备方法同实施例13,此处不再详述。
实施例16
大豆低聚肽饮品成分 | 含量(Kg) |
大豆低聚肽 | 8 |
赤藓糖醇 | 2 |
三氯蔗糖 | 0.025 |
柠檬酸 | 0.25 |
苹果酸 | 0.1 |
L-谷氨酰胺 | 0.3 |
柠檬酸钠 | 0.06 |
维生素B6 | 0.0001 |
镁元素 | 0.001 |
该大豆低聚肽饮品的制备方法同实施例13,此处不再详述。
实施例17
该大豆低聚肽饮品的制备方法同实施例13,此处不再详述。
上述各矿物质元素可添加等元素重量的含相应元素的食用化合物,如:含钙元素化合物可选用碳酸钙、葡萄糖酸钙、柠檬酸钙、乳酸钙、氧化钙、硫酸钙、氯化钙等;含镁元素化合物可选用硫酸镁、氯化镁、氧化镁、碳酸镁、磷酸氢镁等;含铬元素化合物可选用硫酸铬或氯化铬;含硒元素化合物可选用硒酸钠或***钠;含铁元素化合物可选用硫酸亚铁、葡萄糖酸亚铁、柠檬酸铁铵、富马酸亚铁等;含锌元素化合物可选用硫酸锌、氯化锌、乙酸锌、氧化锌或乳酸锌。
试验观察:
一、感官评价实验
以本发明各实施例的大豆低聚肽饮品为实验对象,依次标号1-17,选择进食限制、消化吸收障碍或代谢紊乱人群100人,其中,男50人、女50人为饮用对象,饮食本发明的大豆低聚肽饮品。
其中,实施例的本发明大豆低聚肽饮品,液态制剂直接服用,固态制剂按与水1:10的重量比冲服。对产品的大豆肽味、整体口感进行消费者测试,获得有效样本的实验结果记录如下表1:
表1感官评价实验结果统计表
由消费者的感官评价可以看出,本发明大豆低聚肽饮品均无大豆肽的不良风味,整体口感受到大众喜欢。
二、胃肠手术后患者肠内营养补充
实验对象:选取180例胃肠手术患者,男、女各90人,年龄40-60岁,随机分为18组,每组10人(男女各5人),以服用能全力(热量值1kCal/mL,纽迪希亚制药(无锡)有限公司)作为营养补充的对照组,实施例1-17为与能全力配合使用的实验组。
实验方法:第0组为对照组,服用能全力;1-17组为实验组,服用能全力并依次服食对应实施例1-17的大豆低聚肽饮品。
服用天数:7天。
服用量:对照组服用能全力40ml/kg体重/天,分4次服用/天,作为膳食营养唯一来源;实验组服用能全力30ml/kg体重/天+本发明实施例1-17大豆低聚肽饮品10ml/kg体重/天(其中实施例13-17的粉剂,20g/袋,加水稀释至200ml),分4次服用/天,作为膳食营养唯一来源;服用方式:经口进食或管饲。
评价指标:患者从入院至出院期间体重减轻情况和住院时间长短,以此为指标评价对患者的营养改善效果,如下表2。
表2胃肠手术后患者肠内营养补充效果试验结果统计表
组别 | 体重减轻平均值/kg | 患者住院时间 |
0 | 3.91±0.62 | 21天 |
1 | 2.68±0.53b | 16天 |
2 | 3.32±0.71a | 17天 |
3 | 2.40±0.94a | 15天 |
4 | 2.83±0.85a | 20天 |
5 | 2.71±0.88a | 15天 |
6 | 2.19±0.60a | 19天 |
7 | 2.20±1.10a | 14天 |
8 | 3.02±0.78b | 15天 |
9 | 2.51±0.91a | 16天 |
10 | 2.84±0.61a | 17天 |
11 | 2.31±0.97a | 18天 |
12 | 1.92±0.81a | 14天 |
13 | 2.38±0.75a | 15天 |
14 | 2.67±0.50a | 17天 |
15 | 2.61±0.65a | 15天 |
16 | 2.80±0.89a | 18天 |
17 | 2.13±0.79a | 16天 |
注:与0组(对照组)比较,aP<0.05,有显著性差异;b P>0.05,无显著性差异。
如表2所示,目前,大部分胃肠手术患者采用补充能全力方式以弥补因无法正常饮食造成的体重减轻。与对照组只服用能全力相比,本发明实施例1-17的大豆低聚肽饮品,作为能全力伴侣用于胃肠手术后患者肠内营养补充,体重减轻和患病住院天数均有改善;其中实施例1和实施例8在体重减轻改善中较对照组无显著性差异,考虑到影响体重的因素较多,病人体质差异、心理素质不同及并发症等因素影响;其余实施例在体重减轻改善方面均有显著性差异。因此,实施例的大豆低聚肽饮品可有效降低患者的体重减轻程度及缩短住院时间,在改善患者营养状况方面具有显著效果。
将本发明的大豆低聚肽饮品与能全力等特殊医学用途食品配合使用,是本发明应用方面的创新,不但能够降低术后病人的住院成本,减轻负担,而且能从健康角度,保证病人机体营养的全面摄入及补充。
三、低蛋白血症患者营养补充
实验对象:选取180例低蛋白血症患者,男、女各90人,年龄45-55岁,随机分为18组,每组10人,以服用安素(粉剂,4.5kCal/ml,雅培制药有限公司,产地:荷兰)作为营养补充的对照组,实施例1-17为实验组。
实验方法:0组服用安素,作为对照组;1-17组依次服用对应实施例1-17的大豆低聚肽饮品作为实验组。对照组和实验组其他饮食相同。服用天数:7天。服用量:对照服用组安素,1g/kg体重/天;实验组服用实施例1-17的大豆低聚肽饮品,实施例1-12为5ml/kg体重/天,实施例13-17为1g/kg体重/天。服用方式:均分为2次/天服用,粉剂溶于5倍温开水中充分溶解后服用。
评价指标:患者7天后体重增加情况及血清总蛋白增加情况,以此为指标评价对患者的营养改善效果,如下表3。
表3低蛋白血症患者营养补充效果试验结果统计表
注:与0组(对照组)比较,aP<0.05,有显著性差异;b P>0.05,无显著性差异。
如表3所示,与对照组对比,将本发明实施例1-17的大豆低聚肽饮品用于低蛋白血症患者的营养补充,7天后的体重和血清总蛋白均有所增加。体重方面,实施例6较对照组无显著性差异,其余实施例均有显著性差异;血清总蛋白方面,实施例6和实施例16较对照组无显著性差异,其余实施例均有显著性差异。因此,实施例1-17可以有效增加低蛋白血症患者的体重并增加血清总蛋白含量,在改善患者营养状况方面具有显著效果。
Claims (10)
1.一种大豆低聚肽饮品,其特征是:其活性成分包括以下重量份数的原料:大豆低聚肽8-20份、复合甜味剂0.13-2.2份、复合酸味剂0.3-0.6份、柠檬酸钠0.02-0.1份、维生素B族0.0001-0.05份、矿物质0.001-0.2份。
2.根据权利要求1所述的一种大豆低聚肽饮品,其特征是:其活性成分还包括氨基酸0.3-10份。
3.根据权利要求1所述的一种大豆低聚肽饮品,其特征是:所述大豆低聚肽饮品的剂型为液态制剂。
4.根据权利要求2所述的一种大豆低聚肽饮品,其特征是:所述大豆低聚肽饮品的剂型为液态制剂或固态制剂。
5.根据权利要求3所述的一种大豆低聚肽饮品,其特征是:所述液态制剂的原料组成为:大豆低聚肽8-20份、复合甜味剂0.13-2.2份、复合酸味剂0.3-0.6份、柠檬酸钠0.02-0.1份、维生素B族0.0001-0.05份、矿物质0.001-0.2份、纯净水64-94份。
6.根据权利要求4所述的一种大豆低聚肽饮品,其特征是:所述液态制剂的原料组成为:大豆低聚肽8-20份、复合甜味剂0.13-2.2份、复合酸味剂0.3-0.6份、柠檬酸钠0.02-0.1份、氨基酸0.3-10份、维生素B族0.0001-0.05份、矿物质0.001-0.2份、纯净水64-94份;所述固态制剂的原料组成为大豆低聚肽8-20份、复合甜味剂0.13-2.2份、复合酸味剂0.3-0.6份、柠檬酸钠0.02-0.1份、氨基酸0.3-10份、维生素B族0.0001-0.05份、矿物质0.001-0.2份。
7.根据权利要求1-6任一所述的一种大豆低聚肽饮品,其特征是:所述大豆低聚肽液体渗透压为280-320mOsm/L;所述氨基酸为L-谷氨酰胺、L-瓜氨酸、L-半胱氨酸、L-胱氨酸、L-精氨酸、丙氨酸的一种或多种;所述复合甜味剂为赤藓糖醇、三氯蔗糖、纽甜、甜菊糖、罗汉果甜苷中的两种或多种;所述复合酸味剂为柠檬酸和苹果酸的组合;所述维生素B族为维生素B2、维生素B6、维生素B12、烟酸(B3)、泛酸(B5)、生物素酸(B7)、叶酸(B9)的一种或多种;所述矿物质为钙、镁、铬、硒、铁、锌元素的一种或多种。
8.一种制备权利要求3所述的大豆低聚肽饮品的方法,其特征是:包括如下操作步骤:
(1)混料:按上述重量份数,将复合甜味剂、复合酸味剂、柠檬酸钠、维生素B族及矿物质按照等量递增的方式进行预混,得预混料,备用;
(2)向步骤(1)的预混料中加入上述重量份数的大豆低聚肽,混和均匀,得混料A,备用;
(3)溶解:取上述重量份数的纯净水,加热至20-50℃,然后将混料B缓慢倒入纯净水中,搅拌至充分溶解,得混合液,备用;
(4)过滤:将步骤(3)的混合液采用孔径0.30-1.0μm的滤膜,在<1.0MPa压力条件下进行纸板过滤,得滤液,备用;
(5)灌装、灭菌:将步骤(4)的滤液灌装,于100-121℃灭菌1-30min,即得。
9.一种制备权利要求4或6所述的大豆低聚肽饮品的方法,其特征是:所述液态制剂的制备包括如下操作步骤:
(1)混料:按上述重量份数,将复合甜味剂、复合酸味剂、柠檬酸钠、氨基酸、维生素B族及矿物质按照等量递增的方式进行预混,得预混料,备用;
(2)向步骤(1)的预混料中加入上述重量份数的大豆低聚肽,混和均匀,得混料B,备用;
(3)溶解:取上述重量份数的纯净水,加热至20-50℃,然后将混料B缓慢倒入纯净水中,搅拌至充分溶解,得混合液,备用;
(4)过滤:将步骤(3)的混合液采用孔径0.30-1.0μm的滤膜,在<1.0MPa压力条件下进行纸板过滤,得滤液,备用;
(5)灌装、灭菌:将步骤(4)的滤液灌装,于100-121℃灭菌1-30min,即得;
所述固态制剂的制备包括如下操作步骤:
(1)混料:按上述重量份数,将复合甜味剂、复合酸味剂、柠檬酸钠、氨基酸、维生素B族及矿物质按照等量递增的方式进行预混,得预混料,备用;
(2)向步骤(1)的预混料中加入上述重量份数的大豆低聚肽,混和均匀,得混料C,备用;
(3)包装:将混料A紫外杀菌后,送入洁净包装间内包装,即得。
10.一种如权利要求1或2所述的大豆低聚肽饮品在特殊医学用途配方食品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710053231.2A CN106723084A (zh) | 2017-01-24 | 2017-01-24 | 大豆低聚肽饮品及制备方法和在特医配方食品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710053231.2A CN106723084A (zh) | 2017-01-24 | 2017-01-24 | 大豆低聚肽饮品及制备方法和在特医配方食品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106723084A true CN106723084A (zh) | 2017-05-31 |
Family
ID=58942531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710053231.2A Pending CN106723084A (zh) | 2017-01-24 | 2017-01-24 | 大豆低聚肽饮品及制备方法和在特医配方食品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106723084A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107518413A (zh) * | 2017-08-15 | 2017-12-29 | 北京盈泰正和生物科技有限公司 | 一种增强免疫力的蛋白低聚肽组合物及其制备方法 |
CN109820123A (zh) * | 2018-11-22 | 2019-05-31 | 赛杜恳医药生物科技(上海)有限公司 | 一种改善微循环的植物饮品及其制备方法 |
CN111202246A (zh) * | 2019-12-28 | 2020-05-29 | 江苏天美健大自然生物工程有限公司 | 一种大豆低聚肽粉剂及其制备方法 |
CN111329072A (zh) * | 2020-03-24 | 2020-06-26 | 广州态好生物科技有限公司 | 一种以大豆短肽为原料的升白蛋白食品 |
CN111493249A (zh) * | 2020-05-25 | 2020-08-07 | 山东博奥克生物科技有限公司 | 一种益生元植物多肽饮品及其制备方法 |
CN111685331A (zh) * | 2020-06-22 | 2020-09-22 | 广东燕岭特医食品有限公司 | 一种促进伤口愈合的大豆短肽营养品及其制备方法 |
CN112971053A (zh) * | 2021-04-20 | 2021-06-18 | 吉林大学 | 一种大豆低聚肽糖果香肠及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101036515A (zh) * | 2006-03-13 | 2007-09-19 | 中食肽灵(北京)生物科技有限公司 | 一种体力恢复保健食品及其制备方法 |
CN103892387A (zh) * | 2012-12-28 | 2014-07-02 | 中粮营养健康研究院有限公司 | 一种碳酸型大豆肽饮料及其制备方法 |
-
2017
- 2017-01-24 CN CN201710053231.2A patent/CN106723084A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101036515A (zh) * | 2006-03-13 | 2007-09-19 | 中食肽灵(北京)生物科技有限公司 | 一种体力恢复保健食品及其制备方法 |
CN103892387A (zh) * | 2012-12-28 | 2014-07-02 | 中粮营养健康研究院有限公司 | 一种碳酸型大豆肽饮料及其制备方法 |
Non-Patent Citations (3)
Title |
---|
中国食品添加剂和配料协会: "《食品添加剂手册》", 30 September 2012, 中国轻工业出版社 * |
尤玉如: "《乳品与饮料工艺学》", 31 March 2014, 中国轻工业出版社 * |
阮美娟等: "《饮料工艺学》", 31 January 2013, 中国轻工业出版社 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107518413A (zh) * | 2017-08-15 | 2017-12-29 | 北京盈泰正和生物科技有限公司 | 一种增强免疫力的蛋白低聚肽组合物及其制备方法 |
CN109820123A (zh) * | 2018-11-22 | 2019-05-31 | 赛杜恳医药生物科技(上海)有限公司 | 一种改善微循环的植物饮品及其制备方法 |
CN111202246A (zh) * | 2019-12-28 | 2020-05-29 | 江苏天美健大自然生物工程有限公司 | 一种大豆低聚肽粉剂及其制备方法 |
CN111329072A (zh) * | 2020-03-24 | 2020-06-26 | 广州态好生物科技有限公司 | 一种以大豆短肽为原料的升白蛋白食品 |
CN111493249A (zh) * | 2020-05-25 | 2020-08-07 | 山东博奥克生物科技有限公司 | 一种益生元植物多肽饮品及其制备方法 |
CN111685331A (zh) * | 2020-06-22 | 2020-09-22 | 广东燕岭特医食品有限公司 | 一种促进伤口愈合的大豆短肽营养品及其制备方法 |
CN112971053A (zh) * | 2021-04-20 | 2021-06-18 | 吉林大学 | 一种大豆低聚肽糖果香肠及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106723084A (zh) | 大豆低聚肽饮品及制备方法和在特医配方食品中的应用 | |
CN106562162B (zh) | 一种海棠果益生菌发酵饮品及其制备方法 | |
CN103432161B (zh) | 多种维生素矿物质泡腾片及其制备方法 | |
CN101461531B (zh) | 一种脑营养饮料 | |
CN101971951B (zh) | 一种具有保健功能的山药粉及制备方法 | |
CN103598333A (zh) | 一种健脾消食的酸奶及其加工工艺 | |
CN101268835A (zh) | 一种儿童型营养高钙冲剂及其生产制作工艺 | |
CN107232471A (zh) | 一种营养固体饮料 | |
CN102048225B (zh) | 一种具有改善生长发育功能的红枣保健饮料 | |
CN109953231A (zh) | 左旋肉碱饮料及其制备方法 | |
CN115736142A (zh) | 一种益生元西梅纤维果饮的配方及制备工艺 | |
CN101642165A (zh) | 一种减肥酸奶饮料的制作方法 | |
CN103223128B (zh) | 一种改善营养性贫血的中药组合物及其制备方法 | |
CN101700311B (zh) | 一种补气安神营养保健品的制作方法 | |
CN104255916A (zh) | 富硒酸奶及其家庭化生产方法 | |
CN102349671A (zh) | 复合果蔬汁饮料及制备方法 | |
CN104351900A (zh) | 一种以糯米为原料的生物型饮料及其制备方法 | |
CN102106577B (zh) | 天然有机可提高男性睡眠质量的饮料 | |
CN103610057A (zh) | 一种提神健脑的含片 | |
CN101253986B (zh) | 多功能营养复合保健饮料及其制备方法 | |
CN101243874A (zh) | 保健食醋 | |
CN111248324A (zh) | 一种用于阳虚体质的养生茶及其制备方法 | |
CN103621871B (zh) | 一种复合氨基酸保健品及其制备方法 | |
CN102511875A (zh) | 一种适合术后人群饮用的红枣浓浆 | |
CN101983721B (zh) | 具有抗疲劳、补钙功能的苁蓉钙组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190911 Address after: 251200 No. D-52, Building D, Phase II, Yucheng Commercial Port, Dezhou City, Shandong Province Applicant after: Shandong Bowling Bao Beijian Food Co., Ltd. Address before: 251200 Shandong city in Dezhou Province, Yucheng national hi tech Industrial Development Zone, East Ring Road No. 1 Applicant before: Millet in Shandong medicine Conte Food Co. Ltd. |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |